Halozyme Therapeutics (HALO) Reiterated at Market Outperform by Citizens on Beating Q1 Estimates
Citizens analyst Jason Butler reiterated a Market Outperform rating and $92.00 price target on Halozyme Therapeutics (NASDAQ: HALO).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)